Patient characteristics
. | Autologous transplantation . | . | Allogeneic transplantation, HLA identical . | . | ||
|---|---|---|---|---|---|---|
. | Children N = 38 . | Adults N = 37 . | Children N = 19 . | Adults N = 32 . | ||
| Median age, y (range) | 1.7 (< 1-14) | 45.5 (16-71) | 2.8 (1-14) | 37 (18-66) | ||
| Sex | ||||||
| Male (%) | 22 (58) | 19 (51) | 10 (53) | 15 (47) | ||
| Female (%) | 16 (42) | 18 (49) | 9 (47) | 17 (53) | ||
| M/F ratio | 58:42 | 51:49 | 53:47 | 47:53 | ||
| Stem cell source | ||||||
| Bone marrow (%) | 28 (74) | 16 (43) | 18 (95) | 22 (69) | ||
| Peripheral blood (%) | 10 (26) | 21 (57) | 1 (5) | 10 (31) | ||
| Purge of stem cell source | ||||||
| No (%) | 19 (70) | 26 (90) | — | — | ||
| Yes (%) | 8 (30) | 3 (10) | — | — | ||
| Missing | 11 | 8 | — | — | ||
| GVHD prevention | ||||||
| CSA | — | — | 2 | 3 | ||
| MTX | — | — | 3 | 0 | ||
| CSA + MTX | — | — | 10 | 22 | ||
| Tdepl | — | — | 1 | 5 | ||
| TBI conditioning regimen | ||||||
| No (%) | 31 (97) | 24 (70) | 12 (63) | 14 (42) | ||
| Yes (%) | 1 (3) | 10 (29) | 7 (37) | 18 (58) | ||
| Missing | 6 | 3 | ||||
| Time from diagnosis to CRl, d (range) | 77 (28-184) | 49 (25-289) | 48 (29-145) | 69 (18-165) | ||
| Time from diagnosis to transplantation, d (range) | 187 (109-506) | 203 (104-796) | 146 (69-225) | 138 (63-817) | ||
| Median year of transplantation (range) | 1993 (1989-2002) | 1996 (1986-2002) | 1992 (1987-2001) | 1996 (1986-2002) | ||
. | Autologous transplantation . | . | Allogeneic transplantation, HLA identical . | . | ||
|---|---|---|---|---|---|---|
. | Children N = 38 . | Adults N = 37 . | Children N = 19 . | Adults N = 32 . | ||
| Median age, y (range) | 1.7 (< 1-14) | 45.5 (16-71) | 2.8 (1-14) | 37 (18-66) | ||
| Sex | ||||||
| Male (%) | 22 (58) | 19 (51) | 10 (53) | 15 (47) | ||
| Female (%) | 16 (42) | 18 (49) | 9 (47) | 17 (53) | ||
| M/F ratio | 58:42 | 51:49 | 53:47 | 47:53 | ||
| Stem cell source | ||||||
| Bone marrow (%) | 28 (74) | 16 (43) | 18 (95) | 22 (69) | ||
| Peripheral blood (%) | 10 (26) | 21 (57) | 1 (5) | 10 (31) | ||
| Purge of stem cell source | ||||||
| No (%) | 19 (70) | 26 (90) | — | — | ||
| Yes (%) | 8 (30) | 3 (10) | — | — | ||
| Missing | 11 | 8 | — | — | ||
| GVHD prevention | ||||||
| CSA | — | — | 2 | 3 | ||
| MTX | — | — | 3 | 0 | ||
| CSA + MTX | — | — | 10 | 22 | ||
| Tdepl | — | — | 1 | 5 | ||
| TBI conditioning regimen | ||||||
| No (%) | 31 (97) | 24 (70) | 12 (63) | 14 (42) | ||
| Yes (%) | 1 (3) | 10 (29) | 7 (37) | 18 (58) | ||
| Missing | 6 | 3 | ||||
| Time from diagnosis to CRl, d (range) | 77 (28-184) | 49 (25-289) | 48 (29-145) | 69 (18-165) | ||
| Time from diagnosis to transplantation, d (range) | 187 (109-506) | 203 (104-796) | 146 (69-225) | 138 (63-817) | ||
| Median year of transplantation (range) | 1993 (1989-2002) | 1996 (1986-2002) | 1992 (1987-2001) | 1996 (1986-2002) | ||
CsA indicates cyclosporin A; —, not applicable; MTX, methotrexate; and Tdepl, T-cell depletion.